Cardiovascular pharmacology of aging.
Despite the relative paucity of drug trials in the old and especially the very old (> 85 years), some general principles of pharmacology in the aging patient can be taken from available data and clinical experience. The pharmacokinetic changes most consistently seen with aging occur in the volume of distribution, clearance, and half-life of a drug. Renal drug clearance is consistently diminished with aging. Hepatic metabolism is more variably affected, and in contrast to renal clearance, no reliable formula exists to estimate hepatic drug clearance. Pharmacodynamic changes, although present, are less well studied or described in the elderly. Drug interactions and adverse drug reactions increase with increasing numbers of medications prescribed and represent a complex interplay of age, underlying disease, and number and types of medications. The clinical caveats that apply to drug prescription in the very old include reduced starting doses with slow incremental increases; elimination of unnecessary medications; and anticipating and monitoring for drug interactions and ADRs, especially when prescribing warfarin, digoxin, and amiodarone. Future studies that look at the aging patient in the presence of effects of age, physiology, gender, comorbid illness, and multiple drug therapies may help evolve a new set of paradigms for geriatric drug prescribing.
Podrazik
P M
PM
Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA.
Schwartz
J B
JB
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000502:physiology*; D002317:Cardiovascular Agents / Q000493:pharmacokinetics* / Q000494:pharmacology* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism
D002317:Cardiovascular Agents